Arthritis Drug Seen Lowering GvHD Risk
Abatacept (Orencia), an immunomodulatory drug approved for rheumatoid arthritis, dramatically reduced the incidence of acute graft versus host disease (GvHD) in patients undergoing HLA-mismatched unrelated donor stem-cell transplants, preliminary clinical data suggested. If the preliminary results hold up in an ongoing randomized trial, use of abatacept could have a major impact on outcomes of high-risk transplants, Dr. Leslie Kean of Seattle Children's Research Institute said at the American Society of Hematology meeting.
About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.